Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20092093 | 0.76 | HTT (0.45) | HTTMAPTALDH1A1HPGDKMT2A | |
| SCHEMBL20150159 | 0.74 | HTT (0.51) | HTTMAPTALDH1A1HTR6 | |
| SCHEMBL19456984 | 0.73 | HTT (1.00) | HTTMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL20150186 | 0.72 | TSHR (0.64) | MAPTALDH1A1LMNAKMT2ACYP3A4 | |
| SCHEMBL30923148 | 0.71 | HTT (0.68) | HTTMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL20501067 | 0.71 | HTT (0.68) | HTTMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL28419784 | 0.69 | MAPT (0.64) | HTTMAPTALDH1A1HPGDLMNA | |
| SCHEMBL29788602 | 0.69 | MAPT (0.64) | HTTMAPTALDH1A1HPGDLMNA | |
| SCHEMBL17720566 | 0.68 | HTT (0.53) | HTTMAPTALDH1A1HPGDLMNA | |
| SCHEMBL10566357 | 0.68 | HTT (0.61) | HTTMAPTALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HTT 1087/4885MAPT 1236/4885ALDH1A1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.